IDEAYA is eligible to receive ~$485M in development & regulatory milestones, ~$20M in preclinical & clinical milestones to advance Pol Theta helicase DC in early P-I trial, ~$475M in commercial milestones along with royalties
GSK gets an exclusive license globally to develop and commercialize the Pol Theta helicase inhibitor DC & will be responsible for all R&D costs of the program
The companies collaborated on IND-enabling studies to support Pol Theta helicase DC in combination with niraparib for patients harboring tumors with BRCA or other HR mutations/HRD. The companies will submit IND for Pol Theta helicase DC to initiate first-in-human studies in H1’23, following the completion of IND-enabling studies
Ref: PRNewswire | Image: IDEAYA
